Ensysce Biosciences, Inc 8-K, filed Jun 27, 2022
Ensysce Biosciences, Inc. (ENSC)
About this 8-K
Ensysce Biosciences, Inc filed this 8-K on June 27, 2022.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTC Pink Open Market |
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
(a) The annual meeting of stockholders of Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) was held on June 23, 2022 (the “Annual Meeting”).
(b) Two proposals were submitted to the Company’s stockholders.
1. The stockholders elected the Company’s three Class I Directors, with terms expiring in 2025:
| Name | For | Against | Abstentions | Broker Non-Votes | ||||||||||||
| Andrew B. Benton | 15,143,513 | 180,580 | 2,510,320 | 6,768,343 | ||||||||||||
| William Chang | 15,119,796 | 206,497 | 2,508,120 | 6,768,343 | ||||||||||||
| Lee Rauch | 17,649,014 | 179,625 | 5,774 | 6,768,343 | ||||||||||||
The votes properly cast “FOR” each nominee’s election exceeded the votes properly cast “AGAINST” such nominee’s election (with “ABSTENTIONS” and broker non-votes not counted as votes cast either “FOR” or “AGAINST”).
2. The stockholders ratified the appointment of the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022:
| For | Against | Abstentions | ||
| 24,416,345 | 181,459 | 4,952 |
The proposal received the affirmative vote of a majority of the outstanding shares of Company common stock present in person (including virtually) or by proxy at the Annual Meeting and entitled to vote thereon. Abstentions had the effect of a vote “AGAINST” the proposal. Broker non-votes had no effect on the proposal.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 27, 2022
| Ensysce Biosciences, Inc. | ||
| By: | /s/ Lynn Kirkpatrick | |
| Name: | Dr. Lynn Kirkpatrick | |
| Title: | President and Chief Executive Officer | |
| 3 |